Generation and characterization of a functional Nanobody against the vascular endothelial growth factor receptor-2; angiogenesis cell receptor

被引:89
|
作者
Behdani, Mandi
Zeinali, Sirous [1 ]
Khanahmad, Hossein
Karimipour, Morteza
Asadzadeh, Nader
Azadmanesh, Keyhan [2 ]
Khabiri, Alireza
Schoonooghe, Steve [3 ,4 ]
Anbouhi, Mahdi Habibi
Hassanzadeh-Ghassabeh, Gholamreza [3 ,4 ]
Muyldermans, Serge [3 ,4 ]
机构
[1] Pasteur Inst Iran, Dept Mol Med, Biotechnol Res Ctr, Tehran 1316543551, Iran
[2] Pasteur Inst Iran, Dept Virol, Tehran 1316543551, Iran
[3] Vrije Univ Brussel, Cellular & Mol Immunol Lab, Brussels, Belgium
[4] VIB, NSF, Dept Biol Struct, Brussels, Belgium
关键词
VEGFR2; Nanobody; Angiogenesis; SINGLE-DOMAIN ANTIBODIES; RAMUCIRUMAB IMC-1121B; INHIBITION; EXPRESSION; FRAGMENTS; SELECTION; IMMUNOGLOBULIN; AFFINITY; THERAPY; VEGFR-2;
D O I
10.1016/j.molimm.2011.11.013
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Vascular endothelial growth factor receptor-2 (VEGFR2) is an important tumor-associated receptor and blockade of the VEGF receptor signaling can lead to the inhibition of neovascularization and tumor metastasis. Nanobodies are the smallest intact antigen binding fragments derived from heavy chain-only antibodies occurring in camelids. Here, we describe the identification of a VEGFR2-specific Nanobody, named 3VGR19, from dromedaries immunized with a cell line expressing high levels of VEGFR2. We demonstrate by FACS, that 3VGR19 Nanobody specifically binds VEGFR2 on the surface of 293KDR and HUVECs cells. Furthermore, the 3VGR19 Nanobody potently inhibits formation of capillary-like structures. These data show the potential of Nanobodies for the blockade of VEGFR2 signaling and provide a basis for the development of novel cancer therapeutics. (c) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:35 / 41
页数:7
相关论文
共 50 条
  • [1] Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis
    Shibuya, Masabumi
    JOURNAL OF BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2006, 39 (05): : 469 - 478
  • [2] Contribution of vascular endothelial growth factor receptor-2 sialylation to the process of angiogenesis
    P Chiodelli
    S Rezzola
    C Urbinati
    F Federici Signori
    E Monti
    R Ronca
    M Presta
    M Rusnati
    Oncogene, 2017, 36 : 6531 - 6541
  • [3] Contribution of vascular endothelial growth factor receptor-2 sialylation to the process of angiogenesis
    Chiodelli, P.
    Rezzola, S.
    Urbinati, C.
    Signori, F. Federici
    Monti, E.
    Ronca, R.
    Presta, M.
    Rusnati, M.
    ONCOGENE, 2017, 36 (47) : 6531 - 6541
  • [4] MAb against vascular endothelial growth factor receptor-2 (KDR)
    Basalp, Aynur
    Yucel, Fatima
    Kumbasar, Asli
    Baysal, Kemal
    HYBRIDOMA, 2006, 25 (04): : 248 - 249
  • [5] Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin
    Lamszus, K
    Brockmann, MA
    Eckerich, C
    Bohlen, P
    May, C
    Mangold, U
    Fillbrandt, R
    Westphal, M
    CLINICAL CANCER RESEARCH, 2005, 11 (13) : 4934 - 4940
  • [6] Elevated Vascular Endothelial Growth Factor Receptor-2 Abundance Contributes to Increased Angiogenesis in Vascular Endothelial Growth Factor Receptor-1-Deficient Mice
    Ho, Vivienne C.
    Duan, Li-Juan
    Cronin, Chunxia
    Liang, Bruce T.
    Fong, Guo-Hua
    CIRCULATION, 2012, 126 (06) : 741 - +
  • [7] Cell-permeable iron inhibits vascular endothelial growth factor receptor-2 signaling and tumor angiogenesis
    Kir, Devika
    Saluja, Manju
    Modi, Shrey
    Venkatachalam, Annapoorna
    Schnettler, Erica
    Roy, Sabita
    Ramakrishnan, Sundaram
    ONCOTARGET, 2016, 7 (40) : 65348 - 65363
  • [8] Expression of vascular endothelial growth factor receptor-2 in Merkel cell carcinoma
    Kukko, Heli
    Koljonen, Virve
    Lassus, Patrik
    Tukiainen, Erkki
    Haglund, Caj
    Bohling, Tom
    ANTICANCER RESEARCH, 2007, 27 (4C) : 2587 - 2589
  • [9] Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2
    Kunkel, P
    Ulbricht, U
    Bohlen, P
    Brockmann, MA
    Fillbrandt, R
    Stavrou, D
    Westphal, M
    Lamszus, K
    CANCER RESEARCH, 2001, 61 (18) : 6624 - 6628
  • [10] Is the effect of melatonin on vascular endothelial growth factor receptor-2 associated with angiogenesis in the rat ovary?
    Kandemir, Yasemin Behram
    Konuk, Esma
    Katirci, Ertan
    Xxx, Feride
    Behram, Mustafa
    CLINICS, 2019, 74